Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
- 17 March 2015
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 16 (1) , 47-53
Abstract
The objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients. At week 4 of each treatment cycle, toxicities and plasma steady-state levels were assessed. Clinical response was assessed after two cycles. Genotyping was performed by using the PCR restriction fragment length polymorphism method. The CC genotype for ABCB1 was associated with a higher sunitinib exposure (76.81 vs 56.55 ng ml−1, P=0.03), higher risk of all-grade rash (RR 3.00, 95% CI 1.17–7.67) and mucositis (RR 1.60, 95% CI 1.10–2.34) and disease progression than compared with the CT/TT genotype. There was a lack of association observed between the CYP3A5 polymorphism and exposure, response and toxicities. The polymorphism of ABCB1 (C3435T) has an important role in the manifestation of toxicities and drug exposure, but not polymorphism of CYP3A5.Keywords
This publication has 33 references indexed in Scilit:
- Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-HydroxylationDrug Metabolism and Disposition, 2011
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose ReductionJapanese Journal of Clinical Oncology, 2010
- A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasmaJournal of Chromatography B, 2009
- MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcomeThe Pharmacogenomics Journal, 2009
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology PatientsClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future researchThe Pharmacogenomics Journal, 2006
- Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlatesBritish Journal of Clinical Pharmacology, 2003
- Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial TumorsJournal of the American Society of Nephrology, 2002